Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
AH Realty Trust, Inc. (AHRT)
NYSEReal EstateReit - DiversifiedSnapshot 2026-11-04
$6.53-3.69%
Close 2026-11-05 · 1-day change
NYSEReal EstateReit - DiversifiedSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for AHRT yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Full-year 2026 FFO per diluted share at $0.51 to $0.55 | It raised its 2026 FFO guidance to $0.51-$0.55 per share. | Intact | FFO guidance falls below $0.51 per share for 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 3 supplied quarters. Management reported: “Third Quarter and Recent Highlights: • Raised full-year 2026 FFO, as Adjusted by 11.5% from original guidance to $0.57 to $0.59 per diluted share, driven by continued NOI growth across the retail and mixed-use office portfolio, debt paydowns from closing the Multifamily Portfolio Sale First Closing sooner than anticipated, and the accretive impact of the Company's share repurchase activity.” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk real estate restructuring and execution story, rather than a proven durable compounder. The long-term thesis is on watch: management has made progress on property sales, debt reduction, and its 2026 outlook, while recent performance remains below its industry cohort.
AHRT is described as cheap versus peers, but the valuation evidence also shows a sizable premium versus peers and an expectations gap of negative 0.32, so the signals are mixed. The priced-in assessment is labeled justified, with low fragility, meaning the evidence does not point to concentrated fragility in expectations; confidence in the valuation model is high.
Near term, management’s execution record is mixed: it has sold nine multifamily properties and reduced net debt to EBITDAre, while two contracted property sales remain to close. Management raised 2026 adjusted funds from operations, or FFO, guidance, a measure of operating cash flow used by real estate companies, and second-quarter FFO was stable year over year. However, the risk label is high, the estimated chance of a near-term miss is 47%, and recent results have been uneven.
The multi-year thesis depends on completing the remaining property sales and sustaining progress on debt reduction and the raised outlook. A guidance cut after the recent increase would damage management credibility; Fed rate cuts could support rate-sensitive real estate, while weakness at sector peers could remove that support.
Over the next one to three years, AHRT’s thesis has real execution progress but remains fragile to missed results, guidance changes, and sector conditions. The evidence supports continued monitoring of the business setup, not a clear fundamental resolution. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Complete sale of 11 multifamily properties for $562 million | AH Realty Trust is selling 11 multifamily properties for $562 million. | Intact | total sales fall short of $562 million by end of 2026-Q1 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 1 of 3 supplied quarters. Management reported: “These forward-looking statements may include comments relating to the current and future performance of the Company’s operating property portfolio, financing activities, as well as acquisitions, dispositions, and the Company’s financial outlook, guidance, and expectations.” “These forward-looking statements may include comments relating to the current and future performance of the Company’s operating property portfolio, financing activities, as well as acquisitions, dispositions, and the Company’s financial outlook, guidance, and expectations.” Delivery assessment Nov 4, 2026 |
Complete $100 million share repurchase program | The company increased its share buyback program to $100 million. | Intact | repurchase program reduced below $100 million | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.15 → $-0.10 · observed estimates
$0.22B → $0.21B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.15 | $215,132,600 | 1 / 2 |
| 2026-07-25 | $0.15 | $215,132,600 | 1 / 2 |
| 2026-07-26 | $0.15 | $215,132,600 | 1 / 2 |
| 2026-07-27 | $0.15 | $215,132,600 | 1 / 2 |
| 2026-07-28 | $0.15 | $215,132,600 | 1 / 2 |
| 2026-07-29 | $0.15 | $215,132,600 | 1 / 2 |
| 2026-07-30 | $0.15 | $215,132,600 | 1 / 2 |
| 2026-07-31 | $0.15 | $215,132,600 | 1 / 2 |
| 2026-08-01 | $0.15 | $215,132,600 | 1 / 2 |
| 2026-08-02 | $0.15 | $215,132,600 | 1 / 2 |
| 2026-08-03 | $0.15 | $215,132,600 | 1 / 2 |
| 2026-08-04 | $0.15 | $217,712,000 | 1 / 2 |
| 2026-08-05 | $0.15 | $217,712,000 | 1 / 2 |
| 2026-08-06 | $0.15 | $217,712,000 | 1 / 2 |
| 2026-08-07 | $0.15 | $212,496,100 | 1 / 2 |
| 2026-08-08 | $0.15 | $212,496,100 | 1 / 2 |
| 2026-08-09 | $0.15 | $212,496,100 | 1 / 2 |
| 2026-08-10 | $0.15 | $212,496,100 | 1 / 2 |
| 2026-08-11 | $0.15 | $212,496,100 | 1 / 2 |
| 2026-08-12 | $0.15 | $212,496,100 | 1 / 2 |
| 2026-08-13 | $0.15 | $212,496,100 | 1 / 2 |
| 2026-08-14 | $-0.29 | $212,496,098 | 1 / 1 |
| 2026-08-15 | $-0.29 | $212,496,098 | 1 / 1 |
| 2026-08-16 | $-0.29 | $212,496,098 | 1 / 1 |
| 2026-08-17 | $-0.29 | $212,496,098 | 1 / 1 |
| 2026-08-18 | $-0.29 | $212,496,098 | 1 / 1 |
| 2026-08-19 | $-0.29 | $212,496,098 | 1 / 2 |
| 2026-08-20 | $-0.10 | $211,697,399 | 1 / 2 |
| 2026-08-21 | $-0.10 | $211,697,399 | 1 / 2 |
| 2026-08-22 | $-0.10 | $211,697,399 | 1 / 2 |
| 2026-08-23 | $-0.10 | $211,697,399 | 1 / 2 |
| 2026-08-24 | $-0.10 | $211,697,399 | 1 / 2 |
| 2026-08-25 | $-0.10 | $211,697,399 | 1 / 2 |
| 2026-08-26 | $-0.10 | $211,697,399 | 1 / 2 |
| 2026-08-27 | $-0.10 | $211,697,399 | 1 / 2 |
| 2026-08-28 | $-0.10 | $211,697,399 | 1 / 2 |
| 2026-08-29 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-08-30 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-08-31 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-01 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-02 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-03 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-04 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-05 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-06 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-07 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-08 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-09 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-10 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-11 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-12 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-13 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-14 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-15 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-16 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-17 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-18 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-19 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-20 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-21 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-22 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-23 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-24 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-25 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-26 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-27 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-28 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-29 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-09-30 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-10-01 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-10-02 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-10-03 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-10-04 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-10-05 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-10-06 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-10-07 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-10-08 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-10-09 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-10-10 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-10-11 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-10-12 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-10-13 | $-0.10 | $212,893,297 | 1 / 2 |
| 2026-10-14 | $-0.10 | $212,893,297 | 1 / 1 |
| 2026-10-15 | $-0.10 | $212,893,297 | 1 / 1 |
| 2026-10-16 | $-0.10 | $212,893,297 | 1 / 1 |
| 2026-10-17 | $-0.10 | $212,893,297 | 1 / 1 |
| 2026-10-18 | $-0.10 | $212,893,297 | 1 / 1 |
| 2026-10-19 | $-0.10 | $212,893,297 | 1 / 1 |
| 2026-10-20 | $-0.10 | $212,893,297 | 1 / 1 |
| 2026-10-21 | $-0.10 | $212,893,297 | 1 / 1 |
| 2026-10-22 | $-0.10 | $212,893,297 | 1 / 1 |
| 2026-10-23 | $-0.10 | $212,893,297 | 1 / 1 |
| 2026-10-24 | $-0.10 | $212,893,297 | 1 / 1 |
| 2026-10-25 | $-0.10 | $212,893,297 | 1 / 1 |
| 2026-10-26 | $-0.10 | $212,893,297 | 1 / 1 |
| 2026-10-27 | $-0.10 | $212,893,297 | 1 / 1 |
| 2026-10-28 | $-0.10 | $212,893,297 | 1 / 1 |
| 2026-10-29 | $-0.10 | $212,893,297 | 1 / 1 |
| 2026-10-30 | $-0.10 | $212,893,297 | 1 / 1 |
| 2026-10-31 | $-0.10 | $212,893,297 | 1 / 1 |
| 2026-11-01 | $-0.10 | $212,893,297 | 1 / 1 |
| 2026-11-02 | $-0.10 | $212,893,297 | 1 / 1 |
| 2026-11-03 | $-0.10 | $210,910,297 | 1 / 1 |
| 2026-11-04 | $-0.10 | $210,910,297 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 1 Hold · 1 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.